About this trial
Group 1 will include 20 patients aged 18 years and over, American Society of Anesthesiologist (ASA) II-III class, who will undergo supratentorial tumor surgery, and Group 2 will include 20 patients who will undergo pituitary surgery without mannitol. Total intravenous anesthesia (TIVA) will be adjusted to propofol 4 µg/dl and remifentanil 2-4 µg/dl with target-controlled infusion pumps. In the mannitol group, 2.5 ml/kg (0.5 g/kg) will be given to all patients 20 minutes after induction and the mannitol infusion will be adjusted to be 10 minutes.In Group 2, mannitol will not be used and 2.5 ml/kg isotonic will be administered in 10 minutes. Both blood and urine samples will take for measurement to propofol levels.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
American Society of Anesthesiologist (ASA) II participants
supratentorial tumor surgery
eligible for mannitol use
eligible for Total intravenous anesthesia (TIVA)
Disqualifiers
American Society of Anesthesiologist (ASA) III and upper
Chronic kidney failure
sepsis
multiorgan failure
Trial design
Parallel
Treatments tested in this trial
mannitol
Drug2.5 mg/kg Mannitol will be given intravenously
Saline
Other intervention2.5 ml/kg saline will be given as plasebo
Treatment groups
Trial outcomes
Primary outcomes
Serum propofol levels
Blood samples will be taken during study and then propofol levels will measure at the end of study.
Secondary outcomes
Urine propofol levels
Urine samples will take during total intravenous anesthesia (TIVA). And then urine propofol levels will measure.
Locations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.